Family Medicine and Medical Science Research

ISSN: 2327-4972

OPEN ACCESS Freely available online

Commentary

Clinical Implications of Folic Acid on Homocysteine Levels in Chronic Disease

Vicki Cope*

Department of Obstetrics and Gynaecology, Monash University, Clayton, Australia

ABOUT THE STUDY

Folic acid, also known as vitamin B9, plays an important role in various bodily functions, including DNA synthesis, repair, and methylation. One of its significant roles is in the metabolism of homocysteine, an amino acid that, when elevated, is associated with an increased risk of several chronic diseases. Understanding the clinical implications of folic acid on homocysteine levels is essential for managing and potentially mitigating chronic conditions.

Homocysteine metabolism and folic acid

Homocysteine is an intermediate product in the metabolism of methionine, an essential amino acid obtained from dietary sources. Normally, homocysteine is either remethylated back to methionine or transsulfurated to form cysteine. The remethylation process is folic acid-dependent, requiring folate and vitamin B12 as cofactors. Without adequate folic acid, homocysteine levels can rise, leading to hyperhomocysteinemia, a condition linked to various chronic diseases.

Cardiovascular diseases

Elevated homocysteine levels are recognized as an independent risk factor for Cardiovascular Diseases (CVD). Hyperhomocysteinemia contributes to endothelial dysfunction, promotes oxidative stress, and increase platelet aggregation, all of which are necessary in the pathogenesis of atherosclerosis. Several studies have demonstrated that folic acid supplementation effectively lowers homocysteine levels, potentially reducing the risk of cardiovascular events. For instance, the VISP (Vitamin Intervention for Stroke Prevention) trial indicated that folic acid supplementation could lead to a modest reduction in stroke risk among patients with high homocysteine levels.

Chronic kidney disease

In patients with Chronic Kidney Disease (CKD), elevated homocysteine levels are common due to impaired renal function and decreased clearance. This condition further exacerbates cardiovascular risk in Chronic Kidney Disease (CKD) patients. Research has shown that folic acid supplementation in Chronic Kidney Disease (CKD) patients can lower homocysteine levels, which might contribute to improved cardiovascular outcomes.

Neurodegenerative diseases

Homocysteine's neurotoxic effects have been linked to an increased risk of neurodegenerative diseases, including Alzheimer's disease and other forms of dementia. Elevated homocysteine levels can lead to oxidative stress, excitotoxicity, and DNA damage in neuronal cells. Folic acid, by reducing homocysteine levels, might offer neuroprotective benefits. Clinical trials have provided mixed results, with some showing cognitive benefits and others indicating no significant effect. Nevertheless, maintaining adequate folate levels remains a recommended strategy for potentially lowering dementia risk.

Diabetes and metabolic syndrome

In diabetes and metabolic syndrome, elevated homocysteine levels are associated with increased vascular complications. Hyperhomocysteinemia can exacerbate endothelial dysfunction, insulin resistance, and inflammation. Folic acid supplementation has shown promise in reducing homocysteine levels in diabetic patients, which might help reduce vascular complications. While direct evidence linking folic acid supplementation to improved glycemic control is limited, its role in cardiovascular health underscores its importance in managing diabetes-related complications.

Bone health

Homocysteine's role in bone metabolism is an emerging area of research. Elevated homocysteine levels have been linked to increased risk of fractures and osteoporosis. Homocysteine may interfere with collagen cross-linking, affecting bone strength and integrity. Folic acid, by reducing homocysteine levels, could potentially play a role in maintaining bone health and reducing fracture risk, especially in elderly populations.

Correspondence to: Vicki Cope, Department of Obstetrics and Gynaecology, Monash University, Clayton, Australia, E-mail: copvickii26@yahoo.com

Received: 07-May-2024, Manuscript No. FMMSR-24-33017; **Editor assigned:** 10-May-2024, PreQC No. FMMSR-24-33017 (PQ); **Reviewed:** 28-May-2024, QC No. FMMSR -24-33017; **Revised:** 04-Jun-2024, Manuscript No. FMMSR-24-33017 (R); **Published:** 11-Jun-2024, DOI: 10.37532/2327-4972.24.13.186

Citation: Cope V (2024) Clinical Implications of Folic Acid on Homocysteine Levels in Chronic Disease. J Fam Med Med Sci Res. 13:186.

Cancer

The relationship between homocysteine, folic acid, and cancer is complex and not fully understood. Elevated homocysteine levels have been observed in various cancers, potentially due to disrupted folate metabolism. While folic acid's role in DNA synthesis and repair suggests it could help prevent cancer, excessive folate intake has raised concerns about promoting cancer progression in certain contexts. Therefore, the clinical implications of folic acid supplementation in cancer prevention and treatment require careful consideration and further research.

Practical considerations and recommendations

Folic acid supplementation is generally safe and well-tolerated, making it an accessible intervention for managing elevated homocysteine levels. However, its use should be customi ed toz individual needs, considering potential interactions with other medications and underlying health conditions. For instance, vitamin B12 status should be assessed, as folic acid supplementation can mask B12 deficiency, leading to neurological complications.

The Recommended Dietary Allowance (RDA) for folic acid varies by age, sex, and physiological status (e.g., pregnancy). For adults, the Recommended Dietary Allowance (RDA) is typically around 400 micrograms per day. Supplementation doses for lowering homocysteine levels often range from 400 to 800 micrograms per day, depending on the individual's baseline levels and clinical condition.